View Agent
| Agent Info | |
| Agent: | dacomitinib |
| Synonyms: | PF-00299804 |
| Drug Status For Certain Diseases: | Non-small-cell lung carcinoma(phase III) |
| Classification: | 2nd-generation,irreversible pan-EGFR family tyrosine kinase inhibitor |
| Target: | Epidermal growth factor receptor Proto oncogene protein-c mdm2 Erbb2 tyrosine kinase receptor |
| KEGG Pathway: | NA |
| Wiki Pathway: | ErbB Signaling Pathway Aryl Hydrocarbon Receptor Pathway Hair Follicle Development Bladder Cancer miR-targeted genes in epithelium - TarBase L1CAM interactions Hair Follicle Development Signaling by ERBB2 Gastrin-CREB signalling pathway via PKC and MAPK Integrated Pancreatic Cancer Pathway Integrated Breast Cancer Pathway Aryl Hydrocarbon Receptor miR-targeted genes in muscle cell - TarBase MAPK Signaling Pathway Extracellular vesicle-mediated signaling in recipient cells Signaling Pathways in Glioblastoma AGE/RAGE pathway Signaling by ERBB4 Focal Adhesion Regulation of Actin Cytoskeleton TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer Nanoparticle-mediated activation of receptor signaling PIP3 activates AKT signaling Arylhydrocarbon receptor (AhR) signaling pathway Signaling by EGFR miR-targeted genes in lymphocytes - TarBase Gastric cancer network 2 Spinal Cord Injury EGF/EGFR Signaling Pathway |